Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

A systematic review of the impact of stigma and nihilism on lung cancer outcomes

Suzanne K Chambers12*, Jeffrey Dunn12, Stefano Occhipinti1, Suzanne Hughes3, Peter Baade12, Sue Sinclair4, Joanne Aitken12, Pip Youl12 and Dianne L O’Connell3567

Author affiliations

1 Griffith Health Institute, Griffith University, Brisbane, Australia

2 Cancer Council Queensland, Brisbane, Australia

3 Cancer Council New South Wales, Sydney, Australia

4 National Lung Cancer Program, Cancer Australia, Sydney, Australia

5 School of Population Health and Community Medicine, University of New South Wales, Sydney, Australia

6 School of Medicine and Public Health, University of Newcastle, Newcastle, Australia

7 Sydney Medical School – Public Health, University of Sydney, Sydney, Australia

For all author emails, please log on.

Citation and License

BMC Cancer 2012, 12:184  doi:10.1186/1471-2407-12-184

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2407/12/184


Received:22 December 2011
Accepted:15 April 2012
Published:20 May 2012

© 2012 Chambers et al.; licensee BioMed Central Ltd; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

This study systematically reviewed the evidence on the influence of stigma and nihilism on lung cancer patterns of care; patients’ psychosocial and quality of life (QOL) outcomes; and how this may link to public health programs.

Methods

Medline, EMBASE, ProQuest, CINAHL, PsycINFO databases were searched. Inclusion criteria were: included lung cancer patients and/or partners or caregivers and/or health professionals (either at least 80% of participants had lung cancer or were partners or caregivers of lung cancer patients, or there was a lung cancer specific sub-group focus or analysis), assessed stigma or nihilism with respect to lung cancer and published in English between 1st January 1999 and 31st January 2011. Trial quality and levels of evidence were assessed.

Results

Eighteen articles describing 15 studies met inclusion criteria. The seven qualitative studies were high quality with regard to data collection, analysis and reporting; however most lacked a clear theoretical framework; did not address interviewer bias; or provide a rationale for sample size. The eight quantitative studies were generally of low quality with highly selected samples, non-comparable groups and low participation rates and employed divergent theoretical and measurement approaches. Stigma about lung cancer was reported by patients and health professionals and was related to poorer QOL and higher psychological distress in patients. Clear empirical explorations of nihilism were not evident. There is qualitative evidence that from the patients’ perspectives public health programs contribute to stigma about lung cancer and this was supported by published commentary.

Conclusions

Health-related stigma presents as a part of the lung cancer experience however there are clear limitations in the research to date. Future longitudinal and multi-level research is needed and this should be more clearly linked to relevant theory.

Keywords:
Lung neoplasms; Systematic review; Health-related stigma; Therapeutic nihilism

Background

It is estimated that there were 1.61 million cases of lung cancer diagnosed worldwide in 2008 [1], representing about 12.7% of all new cancers globally. It is the most common cancer among men and the second most common among women [1]. The male:female incidence ratio was approximately 2.1:1, and nearly three-quarters of the cases (71%) were 60 years and over at diagnosis [1]. The highest rates among men were found in Central, Eastern and Southern Europe, Northern America and Eastern Asia, and in Northern America among women [1]. In the more developed countries, incidence rates among males continue to decline, while there is evidence that the increasing rates among females are starting to plateau [2], reflecting previous trends in smoking prevalence. With continuing endemic smoking in many less developed countries, increases in incidence are expected to continue.

Worldwide, contrary to the improved survival outcomes for many other types of cancers, the prognosis for people diagnosed with lung cancer remains poor, with 5-year relative survival being around 6-14% among males and 7–18% among females [2]. Much of this is due to the lack of observable symptoms for early stage lung cancer, meaning that most lung cancers are diagnosed at an advanced stage when treatment options are limited [3-6]. Combined with the high incidence, this poor survival means that lung cancer is the most common cause of cancer-related death worldwide. Due to its high case fatality, lung cancer mortality patterns, including trends over time and international variability, closely resembled those for incidence. Globally there was a male:female lung cancer mortality ratio of 2.2:1 and 75% of lung cancer deaths were among people aged 60 years and over [1].

To date, the key focus of international public health efforts to reduce the lung cancer burden has been to work towards decreasing incidence of the disease through tobacco control [7]. Strategies have included legislation to control the sales and marketing of tobacco products; restrictions on smoking in public spaces; and mass media campaigns to educate the public on the health risks of smoking [8]. These efforts led to dramatic changes in smoking prevalence. In Australia in 1964 male smoking prevalence was 58% and this fell to 21% in 2007, while for women prevalence fell from 28% to 18% [9]. In the United States overall smoking prevalence was 42.4% in 1965 [10] and fell to 19.8% in 2007 [11]. It has been suggested that this public health approach leads to stigmatisation of smokers, and further that stigmatisation of smokers can be viewed as a powerful tool to motivate behaviour change in smokers [12]. The question arises however as to whether this stigmatisation influences the illness experience of people who develop a smoking-related disease.

In this regard it has been proposed that lung cancer patients, more so than those with other cancers, may feel stigmatised by their disease and that this health-related stigma may lead to reluctance to seek treatment as well as having increased feelings of distress about the cancer [13]. Stigma is a complex phenomenon that has been applied to a wide array of contexts and accordingly definitions vary [14]. Stigma as originally defined occurs when society labels someone as tainted and less desirable on the basis of an attribute that marks them out as different [15]. This label connects to a negative stereotype comprising a set of inferred undesirable characteristics that distinguishes the stigmatised class as separate or different to the dominant group. Power is central to the creation of stigma such that stigmatisation cannot occur unless the persons who are labelled as different or deviant feel less powerful than the social group whose views prevail [14].

Stigma is relationship and context-specific where a specific attribute is associated with a negative evaluation that may lead to negative treatment or discrimination and self fulfilling prophecies, stereotype activation, and identity threat [16]. Negative evaluations may be “felt” or “enacted”. A felt negative evaluation is internalised and may lead to shame or guilt associated with having a condition and to the fear of being discriminated against on the grounds of social unacceptability because of that condition. An enacted negative evaluation refers to actual discrimination. Awareness of stigma may influence behaviour in an automatic way amongst those who are stigmatised and others with whom they interact; as well as threatening or harming an individual’s social identity leading to increased stress and poor coping [16].

Supporting this view, stigma has been linked to a broad range of negative outcomes across the domains of mental and physical health, socioeconomic status, and education levels [16]. Health-related stigma may contribute to the burden of illness for both patients and their families through delayed presentation for care, premature termination of treatment, and the amplification of psychological and social morbidity [17,18]. In the case of lung cancer, health-related stigma may be a result of the association between the disease and smoking, the perception of the disease as self-inflicted; its high mortality; and perceptions about the type of death that may be experienced [19,20].

In addition to stigma, it is also proposed that therapeutic nihilism about the treatment of lung cancer may influence patterns of care with regards to patients’ help seeking behaviours; as well as what treatment options health providers will actually offer. Therapeutic nihilism as a concept first arose in the 19th century as a belief that medical science was limited in its ability to treat disease that was considered best left to the healing powers of nature [21]. In more recent times this concept has been applied to the treatment of dementia and mental illness [22]; and lung cancer [23]. Specifically, in the context of lung cancer therapeutic nihilism is defined as the view that medical treatments for this illness are of no value [23]. Commentary suggests that nihilism is a barrier to evidence-based care for lung cancer patients [24,25]. It has also been suggested that lung cancer research is underfunded by both government and community cancer control agencies due to the combined effects of stigma and nihilism and a lack of integration across tobacco control and disease-focussed research [26,27].

The present review aimed to identify and assess current evidence about the influence of stigma and nihilism on outcomes for lung cancer patients including the possible impact of public health programs.

Methods

As a first step three authors (SC, JD and SO) developed a set of key clinical questions to guide the review. These were grouped according to: medical and treatment outcomes; psychosocial outcomes; and public health program impacts. Before finalisation, these questions were reviewed by a working group that included clinicians, researchers and consumers with experience in lung cancer. The questions conformed to guidelines in which the target population, intervention, comparator, and outcome are clearly stated to guide the review process [28] questions are listed below by key area.

Key Area 1: Medical and treatment outcomes

• In people with lung cancer are stigma-related negative self-relevant evaluations associated with late presentation for treatment?

• In people with lung cancer are stigma-related negative self-relevant evaluations associated with poor adherence to treatment?

• In people with lung cancer are stigma-related negative self-relevant evaluations associated with poorer survival?

• In people with lung cancer are nihilistic views about the cancer associated with late presentation for treatment?

• In people with lung cancer are nihilistic views about the cancer associated with poor adherence to treatment?

• In people with lung cancer are nihilistic views about the cancer associated with poorer survival?

• In medical professionals are stigma-related negative evaluations about lung cancer patients associated with patterns of treatment?

• In medical professionals are nihilistic views about lung cancer related to patterns of treatment?

Key Area 2: Psychosocial outcomes

• In people with lung cancer are stigma-related negative self-relevant evaluations associated with lower levels of psychosocial help seeking?

• In people with lung cancer are stigma-related negative self-relevant evaluations associated with greater psychosocial distress?

• In people with lung cancer are stigma-related negative self- relevant evaluations associated with poorer quality of life?

• In people with lung cancer are nihilistic views about the cancer associated with lower levels of psychosocial help seeking?

• In people with lung cancer are nihilistic views about the cancer associated with greater psychosocial distress?

• In people with lung cancer are nihilistic views about the cancer associated with poorer quality of life?

Key Area 3: Impacts of public health programs

• In people with lung cancer do anti-smoking public health campaigns contribute to stigma-related negative self evaluations?

• In people with lung cancer do anti-smoking public health campaigns contribute to nihilism views about lung cancer?

Next, a systematic review from 1st January 1999 to 31st January 2011 for the key clinical questions was undertaken. Medline (1999 – March Week 4, 2011), EMBASE (1999 – Week 13, 2011), PsycINFO (1999 – March Week 4, 2011), CINAHL (1999 – 28/02/2011) and ProQuest (1999-31/01/2011) databases were searched. The searches contained keywords and subject headings, such as “stigma.mp”, “prejudic$”, “nihilis$.mp.”, “exp Shame/”, “exp Blame/” and “exp Nihilism/”, respectively. These searches were coupled with searches containing keywords and sub-headings aimed at identifying lung cancer-based research such as “exp Lung Neoplasms/”. In addition, the Web of Science database was searched for citations of the landmark paper by Chapple et al., 2004. Potentially relevant articles were identified by examining the title and abstract and then retrieved for more detailed evaluation against the inclusion criteria by one reviewer. Their references were reviewed for other potentially relevant articles.

Studies were included if they met the pre-determined inclusion criteria:

• Included lung cancer patients and/or partners or caregivers (either at least 80% of participants had lung cancer or were partners or caregivers of lung cancer patients, or there was a lung cancer specific sub-group analysis) OR included health professionals considering patients with lung cancer;

• Assessed lung cancer specific stigma or nihilism and included an outcome of interest – survival, delayed presentation, treatment adherence or refusal, patterns of care, psychological distress, psychological help seeking or quality of life

OR

Compared stigma or nihilism associated with lung cancer, with stigma or nihilism associated with other cancers

OR

Compared stigma or nihilism experienced by lung cancer patients who had never smoked with stigma or nihilism experienced by those who were former or current smokers

OR

Assessed anti-smoking public health campaigns and the outcomes of lung cancer specific stigma or nihilism;

• Were published in English;

• Were published after 31st December 1998 and prior to 1st February 2011.

Both qualitative and quantitative studies were included. Reviews, editorials, books, dissertations and commentaries were excluded.

The methodological quality of the included studies was assessed independently by two reviewers and differences resolved by consensus with separate criteria for qualitative (SC, SH) and quantitative (SH, DO) studies. The assessment of the quality of qualitative studies is still evolving. Accordingly, a novel assessment form was developed based on criteria held in the literature to denote high quality [29-31]. Criteria included whether: the sampling frame was described, justified, or met; the framework for the study design, methodology and orientation disclosed; interviewer bias was addressed; the method of analysis was described; reliability and validity checks were included; data were clearly presented. To assess the quality of the design of included quantitative cross-sectional studies a tool was adapted from established tools for cohort and case–control studies [32] focussing on representativeness of the study sample (subject selection), selection bias (comparability of groups) and attrition bias (participation rates).

The characteristics and results of the qualitative and quantitative studies were summarised in tables by one reviewer and then checked by a second reviewer.

Results

Search results

The process of identifying relevant articles for the review is outlined in Figure 1. The combined Medline, EMBASE and PsycINFO database search identified 3378 citations. On examination of titles and abstracts, 279 were considered potentially relevant. The CINAHL, ProQuest and Web of Science Citation searches identified another 7, 3 and 2 potentially relevant citations respectively. Another 14 potentially relevant citations were identified from retrieved articles. In total, 305 potentially relevant articles were retrieved. Of these, eighteen articles met the inclusion criteria for the review: 9 articles described 7 qualitative studies and 9 articles described 8 quantitative studies. Of the quantitative studies, seven were cross-sectional and one was a cohort study but only the baseline cross-sectional data were relevant to this review. Of the 287 excluded articles most did not assess stigma or nihilism specifically associated with lung cancer.

thumbnailFigure 1. Final process of inclusion and exclusion of studies for the literature review.

Study quality

The characteristics of the included studies are displayed in Tables 1, 2, and 3. The methodological quality of the included studies is summarised in Tables 4 and 5. Most qualitative studies provided a rationale for sample selection, but a clear rationale for sample size was less common. Only one study [33] provided a qualitative framework and interviewer bias was only addressed in two studies [34,35]. However, use of objective methods for data collection was uniform; most studies included some checks for data credibility; and data presentation was clear in all studies. The qualitative studies were all undertaken with participants in the United Kingdom or North America. Based on the criteria devised by Daly et al. 2007 [30], six were level III studies and one was level IV with data presented for only one lung cancer patient [35].

Table 1. Characteristics and results of qualitative studies on stigma and nihilism in lung cancer

Table 2. Table of characteristics of included quantitative studies of patients’ perceptions and caregivers’ attitudes

Table 3. Table of characteristics of included quantitative studies of health professionals’ perceptions of lung cancer

Table 4. Methodological quality of included qualitative studies (n = 7)

Table 5. Methodological quality of included quantitative studies (n = 8)

All of the quantitative studies provided cross-sectional data (level IV evidence) using divergent theoretical and measurement approaches (Tables 2 and 3). All but two of the studies [36,37] used samples from highly selected populations, limiting the generalisability of the findings. Three studies reported correlations between measures on the same individuals [36,38,39] and of the remaining five studies, only one compared outcomes in groups that were comparable on important potential confounding factors [37]. All had low participation rates with important differences between participants and non-participants or did not report whether there were important differences.

Lung cancer related stigma

The results from the qualitative studies are summarised in Table 1; and quantitative results are summarised in Tables 6, 7, and 8. The qualitative studies identified health-related stigma as part of the experience of lung cancer. Patients reported feeling stigmatised by the prevailing view that if someone had lung cancer they would necessarily be a smoker and have inflicted this disease on themselves; and this view was seen by patients as unfair [20,40]. Patients feared that they would be denied treatment and thought that lung cancer was neglected in research and screening because of the link between smoking and lung cancer [20,41,42]. Social workers working with lung cancer patients reported very similar themes when discussing their perceptions of the lung cancer experience [34]. It was proposed that the association of lung cancer with smoking led to lung cancer patients feeling stigmatised, from which guilt, blame and shame arises. This stigma was internalised by patients and led to a division amongst lung cancer patients between smokers who ‘deserve their cancer’ and non-smokers who do not. The view that lung cancer is mostly fatal was also described as another form of stigma.

Table 6. Results of quantitative studies comparing different patient groups

Table 7. Results of quantitative studies examining effects of stigma-related negative evaluations on psychosocial outcomes

Table 8. Results of quantitative studies examining effects of nihilistic views of health professionals on medical and treatment outcomes

Two quantitative studies examined the level of stigma and stigma related outcomes such as blame in different patient groups (Table 6). Perceived stigma was greater for lung cancer patients and guilt, shame and blame were greater for those lung cancer patients who had a history of smoking. In a study of patients with advanced cancer, lung cancer patients reported more perceived cancer-related stigma (measured by a five item instrument) compared to breast and prostate cancer patients but there was no significant difference in the levels of perceived stigma (measured by a single item) between lung, breast and prostate cancer patients [43]. While levels of guilt and shame were not significantly higher for lung cancer patients compared with breast or prostate cancer (individually or combined), within the lung cancer cohort current or former smokers had higher guilt and shame than never smokers. The second study [44] found that caregiver blame regarding the patients’ efforts to control the disease was greater for patients who were current or former smokers compared with never smokers.

Stigma and medical and treatment outcomes

There were no studies evaluating the possible effects of stigma-related negative evaluations on adherence to treatment, survival or patterns of care. There were no quantitative studies examining the effects of stigma-related negative evaluations on late presentation. Four qualitative studies identified smoking related stigma as a possible reason for late presentation (Table 1). In Chapple 2004, a patient with mesothelioma felt that smoking associated stigma resulted in lung cancer symptoms not being taken seriously which then resulted in delays in diagnosis [20]. In Corner 2005 a patient reported an expectation and social view that treatment for lung disease would likely be denied to smokers, and this was given as a reason for delay in seeking medical treatment for symptoms [41,42]. Tod et al. (2008) [40] reported that some patients with lung cancer including non smokers expected to be stigmatised and to be blamed for their disease and so delayed seeking medical help for their symptoms. Health professionals also reported stigma as a reason for lung cancer patients not seeking medical care for symptoms, on the basis of fear that treatment would be denied and fear of negative evaluation [45].

Stigma and psychosocial outcomes

Support group attendance was the only psychosocial help seeking outcome addressed in the literature. Two qualitative studies reported that the stigma associated with lung cancer could lead to difficulties in attending support groups (Table 1) [20,34]. In a survey of recently diagnosed lung cancer patients 10% reported shame would be a potential barrier to support group attendance (Table 7) [39].

The effect of stigma-related negative evaluation on psychological distress was assessed in three quantitative studies (Table 7). Cataldo (2011) [38] followed the approach of Berger at al (2001) [46] to develop a lung cancer-specific measure of health-related stigma. The components considered were precursors (e.g., knowledge about societal attitudes to smoking); perceived stigma (e.g., social isolation, discrimination and shame); and individual responses (e.g., emotional symptoms, behavioural responses). The authors found that higher depression, lower self-esteem, lower social support, poorer social integration and higher social conflict were associated with greater lung cancer specific stigma. Consistent with this, Siminoff et al. (2010) [47] found that stage III and IV lung cancer patients’ depression was greater when they believed that their family blamed them for their cancer. Else-Quest et al., 2009 [48] applied attribution theory and the ‘looking-glass’ model and found that self-blame mediated the link between perceived stigma and adjustment outcomes in lung, breast and prostate cancer patients. However, differences were found in the mediational pathways between cancer patient groups. Perceived stigma and self-blame explained more of the variance in self-esteem, anger, anxiety, and depressed affect in lung cancer patients compared to patients with breast or prostate cancer. Lung cancer patients were also more likely to indicate that their own behaviour contributed to their cancer. In a group of patients with advanced lung cancer anxiety, anger and depression were associated with perceived stigma (measured by a single item). These associations were partly explained by self-blame which was also associated with increased anger, depression and anxiety [48].

In two qualitative studies lung cancer patients and oncology social workers reported that the perception of lung cancer as a self-inflicted disease that leads to a horrible death results in social isolation (Table 1) [20,34]. A lung cancer patient also reported being reluctant to seek financial help as a result of shame, however in the quotes reported it was not clear that this in itself was linked to the type of cancer [49].

Two quantitative studies (Table 7) examined the effects of stigma or related outcomes on quality of life. One found that poorer quality of life was associated with greater lung cancer specific stigma [38]. The other study applied the theory of social motivation, justice and moral emotions (2000) [50] to assess how illness attribution reactions influence caregiver behaviour and found that primary caregiver blame was not associated with their reported assistance to the patient in coping with lung cancer and its symptoms [44].

Lung cancer related nihilism

Qualitative studies reported that lung cancer was seen by patients as a fatal disease (Table 1) [34,35,40]. No empirical studies directly addressed therapeutic nihilism, which may reflect difficulties in operationalising and measuring this construct. Consistent with this, no instruments purporting to directly measure therapeutic nihilism were identified. There was some indirect evidence of greater therapeutic nihilism with respect to lung cancer in the primary care setting (Table 6) [37]. A single quantitative study examining physicians’ referral preferences in response to various scenarios found that physicians were less likely to refer advanced lung cancer patients to an oncologist compared to patients with advanced breast cancer except for supportive or palliative care, and they were less likely to believe in the survival benefits of chemotherapy for resected stage Ib or metastatic lung cancer. It was proposed that this may at least in part be due to nihilism about lung cancer as a disease with a poor prognosis that warrants a less aggressive treatment approach [37].

Nihilism and medical and treatment outcomes

There were no studies evaluating the possible effects of patients’ nihilistic views about lung cancer on survival. No quantitative studies examined the effect of patients’ nihilistic views about lung cancer on delays in presentation or treatment adherence. Table 1 shows the results for the three qualitative studies that identified patient nihilism as a possible factor influencing medical and treatment outcomes. Two qualitative studies identified nihilism as a possible reason for patients’ delays in seeking medical treatment for their symptoms [35,40] and a third qualitative study found that one of the reasons why patients refused recommended treatments and investigations for lung cancer was that they believed treatment was futile [33].

Two quantitative studies approached the question of therapeutic nihilism by measuring beliefs regarding a survival benefit for chemotherapy (Table 8). Schroen [51] used the underestimation of 5-year survival for Stage I disease as an indicator of pessimism about treatment. In this study those categorised as pessimistic were significantly less likely to believe in a survival benefit for chemotherapy in addition to radiotherapy for unresectable locally advanced non small cell lung cancer (NSCLC). An Australian study [36] found a wide variation in knowledge about chemotherapy for metastatic lung cancer and concluded that pulmonary physicians, radiation oncologists and palliative care physicians most often rated chemotherapy as not useful in this setting compared to medical oncologists. However this study did not examine the effect of pessimism on referrals for chemotherapy, rather chemotherapy referral for stage IV NSCLC was one of the items that contributed to the measure of pessimism.

Nihilism and psychosocial outcomes

No studies were found that evaluated the possible effects of patient or medical practitioner nihilism on psychosocial outcomes.

Impact of public health anti-smoking programs

This review focused on the views of patients and of health professionals. While authors of several of the qualitative studies raised the issue of the effect of anti-smoking public health campaigns on patient or health professional stigma and nihilism [20,34,40-42,45], no studies were found that directly examined how or whether anti-smoking campaigns impact on patient or health professional stigma related negative self evaluations or nihilistic views about lung cancer. Qualitative studies did however provide some insights. Lung cancer patients reported that tobacco control advertisements were distressing to watch and that the press reinforced the smoking related stigma [20]. Tod et al., 2008 [40] noted that patients saw information campaigns as contributing “to fatalistic views as they focused on death rather than treatment.”

Discussion

This review suggests that health-related stigma is part of the lung cancer experience. Specifically, patients felt that negative social views about lung cancer being a self-inflicted disease with a mostly fatal outcome meant that treatment might be delayed or denied; and that seeking treatment was futile [20,40-42]. Stigma appears to be experienced more by lung cancer patients than other patient groups; and more by smokers compared to non-smokers [43]. Qualitative research with health professionals mirrored these views [34,45]. Hence, it seems reasonable to conclude, despite the limitations of the research to date with respect to quality and levels of evidence, that stigma is an important issue in the case of people with lung cancer and those close to them.

It is unclear however the extent to which this ‘felt’ health-related stigma actually influences medical and treatment outcomes. Quantitative studies with physicians found evidence of pessimistic views about referral to specialist oncology care for lung cancer patients and an underestimation of survival, with effects greater for some physician sub groups [36,37,51]. However, these studies addressed the issues of stigma and nihilism indirectly. Hence, while it is plausible that these factors do have a negative effect on medical and treatment outcomes for lung cancer patients with regards to presentation for and adherence to treatment, it is not possible on the basis of research to date to confirm or quantify such an effect. Further, the determinants of survival outcomes are likely to be multifactorial including factors such as socioeconomic status and rurality, as well as disease features. Stigma-related negative self-evaluations by lung cancer patients were associated with higher psychological distress and poorer quality of life [38,46,48]. Stigma appears to be internalised as shame, guilt and blame; and the influence of perceived stigma and self blame on outcomes seems to be strong for lung cancer patients [48]. From this it does appear that health-related stigma has a uniquely negative effect on psychosocial outcomes for lung cancer patients.

Therapeutic nihilism was addressed in these studies in an indirect way, through physician self-report of referral or treatment approaches for lung cancer patients. Classical definitions of therapeutic nihilism incorporate beliefs about medical science being limited and potentially harmful; and illness best left to nature [21]. The modern version of the Hippocratic oath includes the statement: “I will apply, for the benefit of the sick, all measures [that] are required, avoiding those twin traps of overtreatment and therapeutic nihilism” [52]. Future research to better operationalise and measure therapeutic nihilism in current times appears warranted and this could usefully include antecedents of this belief as well as therapeutic outcomes.

Limitations in the research with regard to study design, sampling frames and low participation rates were noted. These limitations may be related to a number of factors. First, people with lung cancer are often unwell at the time of diagnosis, or become unwell soon after. This presents challenges in recruitment, assessment, and study retention and this remains an ongoing challenge for researchers in this field [53]. Second, the studies identified did not use consistent theoretical frameworks and the consequent variations in assessment approaches make it difficult to draw strong conclusions from the available evidence. One potential approach would be to incorporate stigma into a broader model of adjustment to cancer, such as transactional models of stress and coping [54,55]. This approach has been previously suggested as a framework for explaining stigma-related identity threat and takes into account collective representations, situational cues, and personal characteristics as precursors that influence threat appraisal from which individual responses and outcomes evolve [16]. Applying this to stigma and cancer links social representations about lung cancer (stigma); situational cues (e.g., anti-tobacco advertisements or smoking-related cues); and personal characteristics and coping resources (e.g., disease stage, optimism, social support) to consider how these shape that person’s cognitive appraisals of the threat the disease poses to their health and future; and their identity. These appraisals then in turn shape the person’s coping responses and influence their psychological outcomes (see Figure 2). This framework may have efficacy in guiding future descriptive research in this area as well as the design of psychosocial interventions.

thumbnailFigure 2. Proposed Model for the influence of stigma on lung cancer outcomes.

It is of note that one study followed a clear and systematic approach to develop a measure of health-related stigma [38]. Specifically, an expert multidisciplinary panel was recruited to modify an existing stigma scale [46] to be relevant to the experience of people with lung cancer, after which an online survey was conducted to confirm the factor structure and check the criterion-related validity and internal consistency of the scale. However, further research is needed to fully establish the construct validity of this scale and this should include evidence of discriminant and predictive validity as well as cross-cultural applicability. While a cancer site-specific stigma scale is difficult to use for comparisons across different cancer types, a benefit is that a more specific scale will tap into the unique aspects of stigma that are associated with lung cancer.

With regards to the impact of public health programs on stigma-related negative self-evaluation in lung cancer patients, qualitative data suggest that media advertisements depicting smoking-related illness may contribute to patients’ distress [20,40]. While data here are sparse, it does seem that a raised social awareness of lung cancer as necessarily smoking-related has contributed to stigma-related negative self-perceptions for lung cancer patients. Commentary on this matter has included consideration of the weighing up of the public benefit that ensues from the decrease in tobacco-related disease when smoking prevalence rates decrease against the potential cost to those who are stigmatised [12,56,57]. Clearly this is a complex matter, however social or community education activities to combat health-related stigma in lung cancer may be needed. In this regard, efforts to reduce health-related stigma in lung cancer will necessarily need to be multilevel. While the impact of stigma on people with lung cancer may be individual and clinical in nature (e.g., increased distress or decreased quality of life), the phenomenon is social in nature. Specifically, stigma arises out of a social context where a characteristic or attribute of a class of people leads them to be negatively stereotyped with consequential disadvantage and compromised outcomes [14,16]. Hence, the social context also needs to be addressed alongside efforts to reduce negative individual sequelae of stigma.

Conclusion

In conclusion, this review suggests that health-related stigma is part of the lung cancer experience; and that it contributes to psychological distress for patients and impairs quality of life. Therapeutic nihilism appears to, at least in part, be embedded in the experience of stigma. How stigma and nihilsm may influence health professional behaviour is unclear. It seems clear that there are deficits in health professionals’ knowledge about contemporary evidence-based lung cancer care and this needs to be addressed. Moreover, longitudinal research to examine the relative influence of individual level variables (e.g., stigma-related negative self-perceptions); and group level factors (e.g., socio-economic and geographic variables) is needed to clearly identify targets for change. Commentary suggests tobacco control activities may be linked to health-related stigma in lung cancer however this is a complex issue with little clear empirical data on the topic [25,58-60]. More broadly, it has been suggested that there needs to be a dialogue between tobacco control researchers and lung cancer care researchers and clinicians to develop an integrated approach to lung cancer research, policy and services planning [27]. This is an area for future action by health policy makers, health care professionals, and consumer advocates.

Competing interests

There are no competing interests for this paper.

Authors’ contributions

SC and DO’C led the design of the study, undertook data analysis and drafted the manuscript. SH undertook data analysis and helped to draft the manuscript. JD, SO, PB, SS and PY participated in the design of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The project was funded by Cancer Australia under the National Lung Cancer Program. We thank Dr Bronwyn Morris for her input to our quality assessment process. We also acknowledge and thank Profs Kwun Fong and David Ball; Ms Joyce Graham; and Assoc. Profs Shalini Vinod, Gail Garvey and Patricia Valery for their comments on the key clinical questions applied in this review.

References

  1. GLOBOCAN:

    v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancerbase no 10. 2008.

    http://globocan.iarc.fr webcite

    OpenURL

  2. Youlden DR, Cramb SM, Baade PD: The international epidemiology of lung cancer: geographical distribution and secular trends.

    J Thorac Oncol 2008, 3(8):819-831. PubMed Abstract | Publisher Full Text OpenURL

  3. Pirozynski M: 100 years of lung cancer.

    Respir Med 2006, 100(12):2073-2084. PubMed Abstract | Publisher Full Text OpenURL

  4. Ries L, Melbert D, Krapcho M, Mariotto A, Miller B, Feuer E, Clegg L, Horner M, Howlader N, Eisner M: SEER cancer statistics review, 1975–2004. Bethesda, MD: National Cancer Institute; 2007.

  5. Schwartz AG, Prysak GM, Bock CH, Cote ML: The molecular epidemiology of lung cancer.

    Carcinogenesis 2006, 28(3):507-518. PubMed Abstract | Publisher Full Text OpenURL

  6. Spiro SG, Silvestri GA: One hundred years of lung cancer.

    Am J Respir Crit Care Med 2005, 172(5):523. PubMed Abstract | Publisher Full Text OpenURL

  7. US Department of Health and Human Services: Preventing Tobacco Use Among Youth and Young Adults: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2012. OpenURL

  8. Levy DT, Chaloupka F, Gitchell J: The effects of tobacco control policies on smoking rates: a tobacco control scorecard.

    J Public Health Manag Pract 2004, 10(4):338-353. PubMed Abstract | Publisher Full Text OpenURL

  9. Scollo M, Winstanley M: Tobacco in Australia: Facts and Issues. Melbourne: Cancer Council Victoria; 2008. OpenURL

  10. Surveillance for selected tobacco-use behaviors - United States 1900–1994

    2012.

    http://www.cdc.gov/mmwr/preview/mmwrhtml/00033881.htm#00000793.htm webcite

  11. Cigarette smoking among adults and trends in smoking cessation - United States 2008 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5844a2.htm webcite

  12. Stuber J, Galea S, Link BG: Smoking and the emergence of a stigmatized social status.

    Soc Sci Med 2008, 67(3):420-430. PubMed Abstract | Publisher Full Text OpenURL

  13. Raleigh ZT: A biopsychosocial perspective on the experience of lung cancer.

    J Psychosoc Oncol 2010, 28(1):116-125. PubMed Abstract | Publisher Full Text OpenURL

  14. Link BG, Phelan JC: Conceptualizing stigma.

    Annu Rev Sociol 2001, 27:363-385. Publisher Full Text OpenURL

  15. Goffman E: Stigma: Notes on the Management of Spoiled Identity. Simon & Schuster; 1963. OpenURL

  16. Major B, O'Brien LT: The social psychology of stigma.

    Annu Rev Psychol 2005, 56(1):393-421. PubMed Abstract | Publisher Full Text OpenURL

  17. Heijnders M, Van Der Meij S: The fight against stigma: an overview of stigma-reduction strategies and interventions.

    Psychol Health Med 2006, 11(3):353-363. PubMed Abstract | Publisher Full Text OpenURL

  18. Weiss MG, Ramakrishna J, Somma D: Health-related stigma: rethinking concepts and interventions.

    Psychol Health Med 2006, 11(3):277-287. PubMed Abstract | Publisher Full Text OpenURL

  19. Lebel S, Devins GM: Stigma in cancer patients whose behavior may have contributed to their disease.

    Future Oncol 2008, 4(5):717-733. PubMed Abstract | Publisher Full Text OpenURL

  20. Chapple A, Ziebland S, McPherson A: Stigma, shame, and blame experienced by patients with lung cancer: qualitative study.

    BMJ 2004, 328(7454):1470. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  21. Starr P: The Social Transformation of American Medicine. New York: Basic Books; 1982. OpenURL

  22. The American Academy of Neurology Ethics and Humanities Subcommittee: Ethical issues in the management of the demented patient.

    Neurology 1996, 46:1180-1183. PubMed Abstract OpenURL

  23. Ball DL, Irving LB: Are patients with lung cancer the poor relations in oncology?

    Medical Journal of Australia 2000, 172(7):310-311. PubMed Abstract OpenURL

  24. Rengan R, Hahn SM: Introduction: non-small-cell lung cancer and pleural malignancies: the end of the era of therapeutic Nihilism?

    Semin Radiat Oncol 2010, 20(3):147-148. PubMed Abstract | Publisher Full Text OpenURL

  25. Zwitter M: Comments on treatment strategy for locally advanced non-small cell lung cancer.

    Lung Cancer 2002, 38:33-35. OpenURL

  26. Gulyn LM, Youssef F: Attribution of blame for breast and lung cancers in women.

    J Psychosoc Oncol 2010, 28(3):291-301. PubMed Abstract | Publisher Full Text OpenURL

  27. Gritz ER, Sarna L, Dresler C, Healton CG: Building a united front: aligning the agendas for tobacco control, lung cancer research, and policy.

    Cancer Epidemiol Biomarkers Prev 2007, 16(5):859-863. PubMed Abstract | Publisher Full Text OpenURL

  28. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis J, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

    J Clin Epidemiol 2009, 62(10):e1-e34. PubMed Abstract | Publisher Full Text OpenURL

  29. Chwalisz K, Shah SR, Hand KM: Facilitating rigorous qualitative research in rehabilitation psychology.

    Rehabil Psychol 2008, 53(3):387. OpenURL

  30. Daly J, Willis K, Small R, Green J, Welch N, Kealy M, Hughes E: A hierarchy of evidence for assessing qualitative health research.

    J Clin Epidemiol 2007, 60(1):43-49. PubMed Abstract | Publisher Full Text OpenURL

  31. Elliott R, Fischer CT, Rennie DL: Evolving guidelines for publication of qualitative research studies in psychology and related fields.

    Br J Clin Psychol 1999, 38(3):215-229. PubMed Abstract | Publisher Full Text OpenURL

  32. How to use the evidence: assessment and application of scientific evidence http://www.nhmrc.gov.au/guidelines/publications/cp69 webcite

  33. Sharf BF, Stelljes LA, Gordon HS: ‘A little bitty spot and I'm a big man’: patients' perspectives on refusing diagnosis or treatment for lung cancer.

    Psychooncology 2005, 14(8):636-646. PubMed Abstract | Publisher Full Text OpenURL

  34. Conlon A, Gilbert D, Jones B, Aldredge P: Stacked stigma: oncology social workers' perceptions of the lung cancer experience.

    J Psychosoc Oncol 2010, 28(1):98. PubMed Abstract | Publisher Full Text OpenURL

  35. Leydon G, Bynoe-Sutherland J, Coleman M: The journey towards a cancer diagnosis: the experiences of people with cancer, their family and carers.

    Eur J Cancer Care 2003, 12(4):317-326. Publisher Full Text OpenURL

  36. Jennens RR, de Boer R, Irving L, Ball DL, Rosenthal MA: Differences of opinion.

    Chest 2004, 126(6):1985. PubMed Abstract | Publisher Full Text OpenURL

  37. Wassenaar TR, Eickhoff JC, Jarzemsky DR, Smith SS, Larson ML, Schiller JH: Differences in primary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer.

    J Thorac Oncol 2007, 2(8):722. PubMed Abstract | Publisher Full Text OpenURL

  38. Cataldo JK, Slaughter R, Jahan TM, Pongquan VL, Hwang WJ: Measuring stigma in people with lung cancer: psychometric testing of the cataldo lung cancer stigma scale.

    Oncol Nurs Forum 2011, 38(1):46-54. Publisher Full Text OpenURL

  39. Devitt B, Hatton A, Baravelli C, Schofield P, Jefford M, Mileshkin L: What should a support program for people with lung cancer look like? differing attitudes of patients and support group facilitators.

    J Thorac Oncol 2010, 5(8):1227. PubMed Abstract | Publisher Full Text OpenURL

  40. Tod AM, Craven J, Allmark P: Diagnostic delay in lung cancer: a qualitative study.

    J Adv Nurs 2008, 61(3):336-343. PubMed Abstract | Publisher Full Text OpenURL

  41. Corner J, Hopkinson J, Fitzsimmons D, Barclay S, Muers M: Is late diagnosis of lung cancer inevitable? Interview study of patients’ recollections of symptoms before diagnosis.

    Thorax 2005, 60(4):314. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  42. Corner J, Hopkinson J, Roffe L: Experience of health changes and reasons for delay in seeking care: a UK study of the months prior to the diagnosis of lung cancer.

    Soc Sci Med 2006, 62(6):1381-1391. PubMed Abstract | Publisher Full Text OpenURL

  43. LoConte NK, Else-Quest NM, Eickhoff J, Hyde J, Schiller JH: Assessment of guilt and shame in patients with non–small-cell lung cancer compared with patients with breast and prostate cancer.

    Clin Lung Cancer 2008, 9(3):171-178. PubMed Abstract | Publisher Full Text OpenURL

  44. Lobchuk MM, McClement SE, McPherson C, Cheang M: Does blaming the patient with lung cancer affect the helping behavior of primary caregivers?

    Oncol Nurs Forum 2008, 35(4):681-689. PubMed Abstract | Publisher Full Text OpenURL

  45. Tod AM, Joanne R: Overcoming delay in the diagnosis of lung cancer: a qualitative study.

    Nurs Stand 2010, 24(31):35-43. PubMed Abstract OpenURL

  46. Berger BE, Ferrans CE, Lashley FR: Measuring stigma in people with HIV: Psychometric assessment of the HIV stigma scale.

    Res Nurs Health 2001, 24(6):518-529. PubMed Abstract | Publisher Full Text OpenURL

  47. Siminoff LA, Wilson Genderson M, Baker S Jr: Depressive symptoms in lung cancer patients and their family caregivers and the influence of family environment.

    Psycho Oncology 2010, 19(12):1285-1293. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  48. Else-Quest NM, LoConte NK, Schiller JH, Hyde JS: Perceived stigma, self-blame, and adjustment among lung, breast and prostate cancer patients.

    Psychol Health 2009, 24(8):949-964. PubMed Abstract | Publisher Full Text OpenURL

  49. Chapple A, Ziebland S, McPherson A, Summerton N: Lung cancer patients' perceptions of access to financial benefits: a qualitative study.

    Br J Gen Pract 2004, 54(505):589. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  50. Weiner B: Social Motivation, Justice, and the Moral emotions: An Attributional Approach. Lawrence Erlbaum; 2006. OpenURL

  51. Schroen AT, Detterbeck FC, Crawford R, Rivera MP, Socinski MA: Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer.

    Chest 2000, 118(1):129. PubMed Abstract | Publisher Full Text OpenURL

  52. The Hippocratic Oath Today.

    [http://www.pbs.org/wgbh/nova/body/hippocratic-oath-today.html webcite]

    OpenURL

  53. Schofield P, Ugalde A, Carey M, Mileshkin L, Duffy M, Ball D, Aranda S: Lung cancer: Challenges and solutions for supportive care intervention research.

    Palliat Support Care 2008, 6(03):281-287. PubMed Abstract | Publisher Full Text OpenURL

  54. Lazarus RS, Folkman S: Stress, Appraisal, and Coping. New York: Springer Publishing Company; 1984. OpenURL

  55. Smith CA: The self, appraisal, and coping. In Handbook of Social and Clinical Psychology: The Health Perspective. Edited by Elmsford . NY, US: Pergamon Press; 1991. OpenURL

  56. Bayer R: Stigma and the ethics of public health: not can we but should we.

    Soc Sci Med 2008, 67(3):463-472. PubMed Abstract | Publisher Full Text OpenURL

  57. Burris S: Stigma, ethics and policy: a commentary on Bayer's "Stigma and the ethics of public health: not can we but should we".

    Soc Sci Med 2008, 67(3):473-475. PubMed Abstract | Publisher Full Text OpenURL

  58. Coughlan R: Stigma, shame, and blame experienced by patients with lung cancer: Health promotion and support groups have a role.

    BMJ 2004, 329(7462):402-403. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  59. Hansen F, Sawatzky J: Stress in patients with lung cancer: a human response to illness.

    Oncol Nurs Forum 2008, 35(2):217-223. PubMed Abstract | Publisher Full Text OpenURL

  60. Holland JC, Kelly BJ, Weinberger MI: Why psychosocial care is difficult to integrate into routine cancer care: stigma is the elephant in the room.

    J Natl Compr Canc Netw 2010, 8(4):362-366. PubMed Abstract | Publisher Full Text OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/12/184/prepub